argenx SE (NASDAQ:ARGX) Stock Position Boosted by HighTower Advisors LLC

HighTower Advisors LLC lifted its stake in argenx SE (NASDAQ:ARGX) by 11.7% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 4,671 shares of the company’s stock after acquiring an additional 489 shares during the period. HighTower Advisors LLC’s holdings in argenx were worth $2,558,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently made changes to their positions in ARGX. HighVista Strategies LLC raised its holdings in argenx by 8.3% during the third quarter. HighVista Strategies LLC now owns 7,154 shares of the company’s stock worth $3,878,000 after purchasing an additional 550 shares in the last quarter. Hilltop Holdings Inc. bought a new stake in shares of argenx in the 3rd quarter worth $281,000. Checkpoint Capital L.P. lifted its holdings in shares of argenx by 12.6% in the third quarter. Checkpoint Capital L.P. now owns 92,500 shares of the company’s stock valued at $50,142,000 after buying an additional 10,350 shares during the period. Erste Asset Management GmbH bought a new position in argenx during the third quarter valued at about $9,007,000. Finally, Captrust Financial Advisors acquired a new position in argenx during the third quarter worth about $243,000. 60.32% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

ARGX has been the subject of several research reports. Piper Sandler raised their price objective on shares of argenx from $553.00 to $620.00 and gave the company an “overweight” rating in a research report on Friday, November 1st. Raymond James restated a “strong-buy” rating and set a $605.00 target price on shares of argenx in a report on Thursday, October 10th. Baird R W cut argenx from a “strong-buy” rating to a “hold” rating in a report on Friday, November 1st. Wedbush reissued an “outperform” rating and set a $655.00 price objective on shares of argenx in a research note on Tuesday, December 3rd. Finally, Wells Fargo & Company boosted their target price on argenx from $547.00 to $639.00 and gave the stock an “overweight” rating in a research report on Friday, November 1st. Three research analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, argenx currently has a consensus rating of “Moderate Buy” and a consensus target price of $635.11.

argenx Trading Up 0.6 %

ARGX opened at $607.21 on Friday. The stock has a fifty day moving average price of $581.03 and a 200 day moving average price of $513.48. argenx SE has a 1 year low of $327.73 and a 1 year high of $630.00. The stock has a market cap of $36.66 billion, a price-to-earnings ratio of -690.01 and a beta of 0.59.

argenx (NASDAQ:ARGX) last announced its quarterly earnings results on Thursday, October 31st. The company reported $1.39 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.10 by $1.29. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. The business had revenue of $588.88 million during the quarter, compared to analyst estimates of $543.29 million. During the same period in the previous year, the company earned ($1.25) EPS. As a group, sell-side analysts forecast that argenx SE will post 2.2 earnings per share for the current fiscal year.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.